Molecular Partners AG American Depositary Shares
MOLN Real Time Price USDRecent trades of MOLN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MOLN's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
MOLN Revenue by Segment or Geography
New patents grants
-
Patent Title: Darpin based multi-specific t-cell engagers Dec. 05, 2023
-
Patent Title: Designed ankyrin repeat domains with altered surface residues Feb. 14, 2023
-
Patent Title: Ankyrin repeat binding proteins and their uses Oct. 11, 2022
-
Patent Title: Designed ankyrin repeat proteins binding to hepatocyte growth factor Sep. 27, 2022
-
Patent Title: Recombinant binding proteins and their use May. 17, 2022
-
Patent Title: Recombinant binding proteins targeting her2 and serum albumin, and their uses Jul. 21, 2020
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction May. 12, 2020
-
Patent Title: Binding proteins comprising at least two repeat domains against her2 Aug. 06, 2019
-
Patent Title: Capping modules for designed ankyrin repeat proteins Jun. 18, 2019
-
Patent Title: Recombinant binding proteins and their use Dec. 18, 2018
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Dec. 26, 2017
-
Patent Title: Designed repeat proteins binding to serum albumin Oct. 03, 2017
-
Patent Title: Capping modules for designed ankyrin repeat proteins Aug. 01, 2017
-
Patent Title: Recombinant proteins that simultaneously bind hgf, vegf-a and serum albumin, comprising ankyrin repeat domains Oct. 04, 2016
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Mar. 22, 2016
-
Patent Title: Designed repeat proteins binding to serum albumin Mar. 15, 2016
-
Patent Title: Capping modules for designed ankyrin repeat proteins Dec. 29, 2015
-
Patent Title: Designed ankyrin repeat proteins binding to platelet-derived growth factor Oct. 20, 2015
-
Patent Title: Binding proteins inhibiting the vegf-a receptor interaction Dec. 02, 2014
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Apr. 29, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MOLN
Recent picks made for MOLN stock on CNBC
ETFs with the largest estimated holdings in MOLN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MOLN stock a Buy, Sell, or Hold?
- What is the price target for $MOLN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MOLN stock?
- Who owns the most shares of $MOLN stock?
- What funds own $MOLN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MOLN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.